ZA8 Stock Chart & Stats
€19.82
-€0.09(-0.45%)
At close: 4:00 PM EDT
€19.82
-€0.09(-0.45%)
Day’s Range― - ―
52-Week Range€11.70 - €25.15
Previous CloseN/A
Volume0.00
Average Volume (3M)43.00
Market Cap
€1.76B
Enterprise Value€1.91K
Total Cash (Recent Filing)€270.70M
Total Debt (Recent Filing)€268.64M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Nov 10, 2026EPS Estimate
2.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding70,959,240
10 Day Avg. Volume65
30 Day Avg. Volume43
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.39
Price to Sales (P/S)18.72
P/FCF Ratio-57.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€35.04Price Target Upside76.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.14
Revenue Forecast (FY)€259.11M
Bulls Say, Bears Say
Bulls Say
Partnered Product ValidationThe approval validates Zymeworks’ Azymetric platform and expands zanidatamab’s commercial reach. It also strengthens the company’s royalty model, with eligibility for additional milestones and 10%–20% royalties on Jazz territory sales.
Liquidity And Milestone RunwayThe stronger cash balance provides meaningful funding for internal research and operations while reducing near-term financing pressure. Potential regulatory milestones could extend the runway beyond 2028, although that outlook depends on execution.
Clinical Pipeline PotentialEncouraging early efficacy across heavily pretreated ovarian and endometrial cohorts supports ZW191’s potential as a differentiated ADC. Further follow-up and development could broaden the company’s wholly owned pipeline and future partnering options.
Bears Say
Volatile Revenue And Persistent LossesThe sharp revenue decline and widening loss show that earnings remain dependent on irregular collaboration payments rather than a stable recurring base. Continued losses could constrain investment capacity and increase reliance on future milestones or financing.
Negative Cash GenerationPersistent cash consumption means the business does not yet fund its development activities organically. Although liquidity is currently strong, ongoing R&D spending and shareholder returns will gradually reduce flexibility if milestone receipts are delayed.
Partner And Pipeline Execution RiskDependence on Jazz and BeiGene milestones and royalties leaves a meaningful portion of future revenue outside management’s direct control. The ZW1528 delay also highlights development uncertainty that may defer pipeline diversification and future partnering value.
Zymeworks News
ZA8 FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was €11.70 and its highest was €25.15 in the past 12 months.
What is Zymeworks Inc’s market cap?
Zymeworks Inc’s market cap is €1.76B.
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is Nov 10, 2026 which is in 75 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on Aug 06, 2026. The company reported -€0.531 earnings per share for the quarter, missing the consensus estimate of -€0.482 by -€0.05.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is 2.12.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 70,959,240 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -€0.531 in its last earnings report, missing expectations of -€0.482. Following the earnings report the stock price went down -1.869%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Currently, no hedge funds are holding shares in DE:ZA8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€35.04 (76.78% Upside)
€35.04 (76.78% Upside)
Blogger Sentiment
Bullish
DE:ZA8 Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.80%
Trailing 12-Months
Company Description
Zymeworks Inc
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
ZA8 Company Deck
ZA8 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.View all DE:ZA8 earnings summariesZA8 Stock 12 Month Forecast
Average Price Target
€35.04
▲(76.78% Upside)
Technical Analysis
Xencor
―
AnaptysBio
―
Vir Biotechnology
―
AbCellera Biologics
―
Generate Biomedicines, Inc.
―